Effects of somatostatin analog SOM230 on cell proliferation apoptosis and catechnolamine levels in cultured pheochromocytoma cells

Journal of Molecular Endocrinology

Volumn 40, Issue 5-6, 2008, Pages 263-271

  Pasquali, Daniela ^a   Rossi, Valentina ^a   Conzo, Giovanni ^a   Pannone, Giuseppe ^b   Bufo, Pantaleo ^b   de Bellis, Annamaria ^a   Renzullo, Andrea ^a   Bellastella, Giuseppe ^a   Colao, Annamaria ^c   Vallone, Gianfranco ^c   Bellastella, Antonio ^a   Sinisi, Antonio A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CATECHOLAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OCTREOTIDE; PASIREOTIDE; DRUG DERIVATIVE; SOM-230; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; CELL CULTURE; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL SURVIVAL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHEOCHROMOCYTOMA;

ADULT; APOPTOSIS; CASPASE 3; CATECHOLAMINES; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; MIDDLE AGED; OCTREOTIDE; PHEOCHROMOCYTOMA; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 45749096710     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-08-0012     Document Type: Article

References (30)

1. Barakat MT, Meeran K & Bloom SR 2004 Neuroendocrine tumours. Endocrine-Related Cancer 11 1-18.
2. Bruns C, Raulf F, Hoyer D, Schloos J, Luebbert H & Weckbecker G 1996 Binding properties of somatostatin receptor subtypes. Metabolism 45 17-20.
3. Chrisoulidou A, Kaltsas G, Ilias I & Grossman AB 2007 The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine-Related Cancer 14 569-585.
4. Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K & Hoyer D 2002 Drug design at peptide receptors: somatostatin receptor ligands. Journal of Molecular Neuroscience 18 15-27.
5. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP et al. 2001 [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 685-693.
6. Hong SJ, Dawson TM & Dawson VL 2004 Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends in Pharmacological Science 25 259-264.
7. Invitti C, De Martin I, Bolla GB, Pecori Giraldi F, Maestri F, Leonetti G & Cavagnini F 1993 Effect of octreotide on catecholamines plasma levels in patients with chromaffin cell tumors. Hormone Research 40 156-160.
8. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R et al. 2001 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 86 895-902.
9. Kolby L, Bernhardt P, Johanson V, Wangberg B, Muth A, Jansson S, Forssell-Aronsson E, Nilsson O & Ahlman H 2006 Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Annals of the New York Academy of Sciences 1073 491-497.
10. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hansen J & Lehnert H 1997 Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clinical Endocrinology 46 39-44.
11. Koriyama N, Kakei M, Yaekura K, Okui H, Yamashita T, Nishimura H, Matsushita S & Tei C 2000 Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies. Hormone Research 53 46-50.
12. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S & Seino Y 1994 Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Journal of Clinical Investigation 93 1321-1325.
13. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP & Plouin PF 2002 Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clinical Endocrinology 57 629-634.
14. Mannelli M 2006 Management and treatment of pheochromocytomas and paragangliomas. Annals of the New York Academy of Sciences 1073 405-416.
15. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R & Lehnert H 2003 Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. Journal of Clinical Endocrinology and Metabolism 88 5150-5157.
16. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM & Tischler AS 2007 International symposium on pheochromocytoma, pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nature Clinical Practice Endocrinology and Metabolism 2 92-102.
17. Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A & Sinisi AA 2000 Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. Journal of Molecolar Endocrinology 25 63-71.
18. Pasquali D, Pierantoni GM, Fusco A, Staibano S, Colantuoni V, De Bellis A, Bellastella A & Sinisi AA 2004 Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. Journal of Molecolar Endocrinology 33 133-143.
19. Patel YC 1999 Somatostatin and ist receptor family. Frontiers in Neuroendocrinology 20 157-198.
20. Plouin PF, Bertherat J, Chatellier G, Billaud E, Azizi M, Grouzmann E & Epelbaum J 1995 Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial. Clinical Endocrinology 42 289-294.
21. Plouin PF, Duclos JM, Soppelsa F, Boublil G & Chatellier G 2001 Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. Journal of Clinical Endocrinology and Metabolism 86 1480-1486.
22. Scholz T, Eisenhofer G, Pacak K, Dralle H & Lehnert H 2007 Clinical review: current treatment of malignant pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 92 1217-1225.
23. Sinisi AA, Bellastella A, Prezioso D, Nicchio MR, Lotti T, Salvatore M & Pasquali D 1997 Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. Journal of Clinical Endocrinology and Metabolism 82 2566-2569.
24. Sisson JC & Shulkin BL 1999 Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Quarterly Journal of Nuclear Medicine 43 217-223.
25. Soldani C & Scovassi AI 2002 Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7 321-328.
26. Steinsapir J, Carr AA, Prisant LM & Bransome ED Jr 1997 Metyrosine and pheochromocytoma. Archive of Internal Medicine 157 901-906.
27. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B & Parmentier C 1995 Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. Journal of Nuclear Medicine 36 1-6.
28. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Schmid KW, Mann K & Petersenn S 2004 Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors. Endocrine Research 4 931-934.
29. Weckbecker G, Briner U, Lewis I & Bruns C 2002 SOM 230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143 4123-4130.
30. Zatelli MC, Piccin D, Bondanelli M, Tagliati F, De Carlo E, Culler MD & Uberti EC 2003 An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro. Hormone and Metabolic Research 35 349-354.